Clinical research of sodium glycididazole injection combined with concurrent chemoradiotherapy in treatment of primary advanced cervical cancer
10.3760/cma.j.issn.1673-422X.2018.12.005
- VernacularTitle:甘氨双唑钠注射剂联合同期放化疗治疗原发性晚期宫颈癌的临床研究
- Author:
Min WEI
1
;
Lingyan XU
;
Jie HAN
;
Peng WANG
Author Information
1. 青海省人民医院妇科
- Keywords:
Uterine cervical neoplasms;
Sodium glycididazole;
Concurrent chemoradiotherapy;
Curative effect;
Security
- From:
Journal of International Oncology
2018;45(12):727-730
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of sodium glycididazole injection combined with concurrent chemoradiotherapy in treatment of primary advanced cervical cancer.Methods A total of 84 patients with primary advanced cervical cancer were selected from November 2010 to November 2016 in Qinghai Provincial People's Hospital.All the patients were divided into the control group (n =42) and the experimental group (n =42) according to random number table method.The control group was treated with routine chemoradiotherapy,and the experimental group was treated with sodium glycididazole injection based on the control group.The curative effects,levels of serum tumor markers such as squamous cell carcinoma associated antigen (SCC),tissue polypeptide specific antigen (TPS),soluble human major histocompatibility complex-Ⅰ molecular chain related gene A protein (sMICA),hypoxia inducible factor-1α (HIF-1α),human epidermal growth factor receptor 2 (Her-2) and adverse reactions of the two groups were compared.Results Four months after treatment,the total effective rates of the experimental group and the control group were 73.81％ (31/42) and 50.00％ (21/42).The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant (x2 =5.048,P =0.025).Four months after treatment,the levels of SCC [(2.67±0.76) ng/ml vs.(4.10±0.94) ng/ml],TPS [(56.85±6.39) U/L vs.(86.69±12.62) U/L],sMICA [(90.31 ±11.25) ng/L vs.(129.46±16.60)ng/L],HIF-1α [(55.47±7.04) ng/Lvs.(68.07±7.97) ng/L] and Her-2 [(44.64±4.96) U/L vs.(53.07±6.56) U/L] in the experimental group were lower than those in the control group,with statistically significant differences (t =7.667,P ＜ 0.001;t =13.671,P ＜0.001;t =12.653,P＜0.001;t =7.679,P＜0.001;t =6.643,P＜0.001).The occurrence rates of bone marrow suppression of the experimental group and the control group were 23.81％ (10/42) and 21.43％ (9/42),the occurrence rates of gastrointestinal reaction were 19.05％ (8/42) and 14.29％ (6/42),the occurrence rates of abnormal electrocardiogram were 4.76％ (2/42) and 2.38％ (1/42),and the tatal adverse reaction rates were 47.62％ (20/42) and 38.10％ (16/42).The difference of the total adverse reaction rates between the experimental group and the control group was not statistically significant (x2 =0.778,P =0.378).Conclusion The clinical efficacy of sodium glycididazole injection combined with concurrent chemoradiotherapy is definite for primary advanced cervical cancer.This treatment regimen can reduce serum levels of SCC,TPS,sMICA,HIF-1α and Her-2,and not increase the incidence of adverse reactions.
